Market Overview

UPDATE: Citigroup Reiterates Medtronic at Buy Following Kanghui Holdings Deal

Share:
Related MDT
Medtronic CEO On The Company's New Valve Product And How Covidien's Integration Is Progressing
Benzinga's Weekend M&A Chatter

Citigroup maintained its Buy rating on Medtronic (NYSE: MDT) as the company announced the acquisition of Kanghui Holdings (NYSE: KH), thus likely ending its current joint venture with Chinese firm Weigao.

Citigroup noted, "KH is expected to generate $65MM in annual sales in 2012 with growth in excess of 20%. Trauma is 60% of sales and spine is around 33%. The sales level is similar to MDT's current run rate of sales from the Weigao JV but has a higher trauma and lower recon mix. MDT has an option to acquire Weigao's 49% stake in the JV by May 2013 for a range of $450-725MM or the JV would expire in January 2014. Since MDT paid more for KH, we assume either the management fit and/or product mix are considered preferable."

Medtronic closed at $43.48 on Thursday.

Latest Ratings for MDT

DateFirmActionFromTo
Mar 2015BMO CapitalMaintainsOutperform
Feb 2015JefferiesMaintainsBuy
Dec 2014Bank of AmericaMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color News Reiteration M&A Intraday Update Analyst Ratings

 

Related Articles (MDT + KH)

Around the Web, We're Loving...

Get Benzinga's Newsletters